Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Identifieur interne : 000752 ( Main/Exploration ); précédent : 000751; suivant : 000753Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
Auteurs : Paolo Solla [Italie] ; Alfonso Fasano [Canada] ; Antonino Cannas [Italie] ; Cesare Salvatore Mulas [Italie] ; Maria Giovanna Marrosu [Italie] ; Anthony E. Lang [Canada] ; Francesco Marrosu [Italie]Source :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2015.
English descriptors
- KwdEn :
- Aged, Anhedonia (drug effects), Apathy (drug effects), Carbidopa (administration & dosage), Carbidopa (pharmacology), Dopamine Agonists (administration & dosage), Dopamine Agonists (pharmacology), Drug Combinations, Female, Gels, Humans, Infusions, Parenteral, Levodopa (administration & dosage), Levodopa (pharmacology), Male, Middle Aged, Parkinson Disease (drug therapy), Substance Withdrawal Syndrome (etiology).
- MESH :
- chemical , administration & dosage : Carbidopa, Dopamine Agonists, Levodopa.
- drug effects : Anhedonia, Apathy.
- drug therapy : Parkinson Disease.
- etiology : Substance Withdrawal Syndrome.
- chemical , pharmacology : Carbidopa, Dopamine Agonists, Levodopa.
- Aged, Drug Combinations, Female, Gels, Humans, Infusions, Parenteral, Male, Middle Aged.
Abstract
Levodopa-carbidopa intestinal gel infusion (LCIG) is indicated in patients with advanced levodopa-responsive Parkinson's disease (PD) for the treatment of motor fluctuations and dyskinesias unsatisfactorily managed with conventional medication. The outcome of non-motor symptoms - particularly affective and behavioral ones - following LCIG initiation remains scarcely explored, especially with respect to the changes undergone by oral dopaminergic drugs. Here we describe 4 PD patients who developed dopamine agonist withdrawal syndrome (DAWS) symptoms correlated with rapid taper of these drugs after LCIG initiation.
DOI: 10.1016/j.parkreldis.2015.05.018
PubMed: 26071817
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000459
- to stream PubMed, to step Curation: 000459
- to stream PubMed, to step Checkpoint: 000459
- to stream Ncbi, to step Merge: 001B99
- to stream Ncbi, to step Curation: 001B99
- to stream Ncbi, to step Checkpoint: 001B99
- to stream Main, to step Merge: 000753
- to stream Main, to step Curation: 000752
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.</title><author><name sortKey="Solla, Paolo" sort="Solla, Paolo" uniqKey="Solla P" first="Paolo" last="Solla">Paolo Solla</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy. Electronic address: paosol29@yahoo.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name><affiliation wicri:level="4"><nlm:affiliation>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Cannas, Antonino" sort="Cannas, Antonino" uniqKey="Cannas A" first="Antonino" last="Cannas">Antonino Cannas</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Mulas, Cesare Salvatore" sort="Mulas, Cesare Salvatore" uniqKey="Mulas C" first="Cesare Salvatore" last="Mulas">Cesare Salvatore Mulas</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Marrosu, Maria Giovanna" sort="Marrosu, Maria Giovanna" uniqKey="Marrosu M" first="Maria Giovanna" last="Marrosu">Maria Giovanna Marrosu</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><nlm:affiliation>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Marrosu, Francesco" sort="Marrosu, Francesco" uniqKey="Marrosu F" first="Francesco" last="Marrosu">Francesco Marrosu</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26071817</idno><idno type="pmid">26071817</idno><idno type="doi">10.1016/j.parkreldis.2015.05.018</idno><idno type="wicri:Area/PubMed/Corpus">000459</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000459</idno><idno type="wicri:Area/PubMed/Curation">000459</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000459</idno><idno type="wicri:Area/PubMed/Checkpoint">000459</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000459</idno><idno type="wicri:Area/Ncbi/Merge">001B99</idno><idno type="wicri:Area/Ncbi/Curation">001B99</idno><idno type="wicri:Area/Ncbi/Checkpoint">001B99</idno><idno type="wicri:Area/Main/Merge">000753</idno><idno type="wicri:Area/Main/Curation">000752</idno><idno type="wicri:Area/Main/Exploration">000752</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.</title><author><name sortKey="Solla, Paolo" sort="Solla, Paolo" uniqKey="Solla P" first="Paolo" last="Solla">Paolo Solla</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy. Electronic address: paosol29@yahoo.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name><affiliation wicri:level="4"><nlm:affiliation>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Cannas, Antonino" sort="Cannas, Antonino" uniqKey="Cannas A" first="Antonino" last="Cannas">Antonino Cannas</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Mulas, Cesare Salvatore" sort="Mulas, Cesare Salvatore" uniqKey="Mulas C" first="Cesare Salvatore" last="Mulas">Cesare Salvatore Mulas</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Marrosu, Maria Giovanna" sort="Marrosu, Maria Giovanna" uniqKey="Marrosu M" first="Maria Giovanna" last="Marrosu">Maria Giovanna Marrosu</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name><affiliation wicri:level="4"><nlm:affiliation>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>The Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Center, Toronto Western Hospital, Division of Neurology, University of Toronto</wicri:regionArea><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName><orgName type="university">Université de Toronto</orgName></affiliation></author><author><name sortKey="Marrosu, Francesco" sort="Marrosu, Francesco" uniqKey="Marrosu F" first="Francesco" last="Marrosu">Francesco Marrosu</name><affiliation wicri:level="1"><nlm:affiliation>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Movement Disorders Center, Department of Neurology, Institute of Neurology, University of Cagliari, Cagliari</wicri:regionArea><wicri:noRegion>Cagliari</wicri:noRegion></affiliation></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="eISSN">1873-5126</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Anhedonia (drug effects)</term><term>Apathy (drug effects)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (pharmacology)</term><term>Dopamine Agonists (administration & dosage)</term><term>Dopamine Agonists (pharmacology)</term><term>Drug Combinations</term><term>Female</term><term>Gels</term><term>Humans</term><term>Infusions, Parenteral</term><term>Levodopa (administration & dosage)</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Substance Withdrawal Syndrome (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Anhedonia</term><term>Apathy</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Substance Withdrawal Syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Carbidopa</term><term>Dopamine Agonists</term><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Combinations</term><term>Female</term><term>Gels</term><term>Humans</term><term>Infusions, Parenteral</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa-carbidopa intestinal gel infusion (LCIG) is indicated in patients with advanced levodopa-responsive Parkinson's disease (PD) for the treatment of motor fluctuations and dyskinesias unsatisfactorily managed with conventional medication. The outcome of non-motor symptoms - particularly affective and behavioral ones - following LCIG initiation remains scarcely explored, especially with respect to the changes undergone by oral dopaminergic drugs. Here we describe 4 PD patients who developed dopamine agonist withdrawal syndrome (DAWS) symptoms correlated with rapid taper of these drugs after LCIG initiation.</div></front></TEI><affiliations><list><country><li>Canada</li><li>Italie</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Italie"><noRegion><name sortKey="Solla, Paolo" sort="Solla, Paolo" uniqKey="Solla P" first="Paolo" last="Solla">Paolo Solla</name></noRegion><name sortKey="Cannas, Antonino" sort="Cannas, Antonino" uniqKey="Cannas A" first="Antonino" last="Cannas">Antonino Cannas</name><name sortKey="Marrosu, Francesco" sort="Marrosu, Francesco" uniqKey="Marrosu F" first="Francesco" last="Marrosu">Francesco Marrosu</name><name sortKey="Marrosu, Maria Giovanna" sort="Marrosu, Maria Giovanna" uniqKey="Marrosu M" first="Maria Giovanna" last="Marrosu">Maria Giovanna Marrosu</name><name sortKey="Mulas, Cesare Salvatore" sort="Mulas, Cesare Salvatore" uniqKey="Mulas C" first="Cesare Salvatore" last="Mulas">Cesare Salvatore Mulas</name></country><country name="Canada"><region name="Ontario"><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name></region><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E" last="Lang">Anthony E. Lang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000752 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000752 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26071817
|texte= Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26071817" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |